RxDoctor Payments DataLook up a doctor →

Kristen Jessen, MD

Neurology · Soldotna, AKNPI 1629171608

Payments from drug & device makers

$50,890in general payments, 2019–2025

Across 533 payments — averaging $95.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$39K
  • EMD Serono, Inc.$2K
  • Amneal Pharmaceuticals LLC$1K
  • Teva Pharmaceuticals USA, Inc.$976
  • Neurocrine Biosciences, Inc.$795
  • Bristol Myers Squibb$743
  • plus $5K from 40 others

What the payments were for

  • Consulting fees$3,1986%
  • Speaking & faculty fees$35,85070%
  • Travel & lodging$1,5053%
  • Food & beverage$9,89919%
  • Education$4381%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$50,890 in reported general payments places this provider in the 95th percentile of 21 neurology providers in Alaska.

See all neurology providers in Alaska

Medicare billing

Part B allowed, 2024
$70,394
Medicare patients
164
Services billed
2,291

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Gamunex-CImmune Globul G/Gly/Iga Avg 4631$88,843
Nurtec OdtRimegepant Sulfate35$57,791
QuliptaAtogepant49$56,595
UbrelvyUbrogepant26$28,617
Aimovig AutoinjectorErenumab-Aooe29$23,573
Topiramate ErTopiramate15$22,648
Lamictal XrLamotrigine12$21,645
Lacosamide56$3,745
Entacapone28$3,096
Carbidopa-LevodopaCarbidopa/Levodopa114$2,775
Memantine Hcl71$1,999
Lamotrigine109$913
Gabapentin55$783
Carbidopa-Levodopa ErCarbidopa/Levodopa14$712
Levetiracetam ErLevetiracetam13$653

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieQulipta, Ubrelvy$39,389$85,21275 claims
PfizerNurtec Odt$149$57,79135 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 21 neurology providers in Alaska.

Other neurology in Soldotna

See the full list for Alaska

Where these figures come from

Is this you, or does something look wrong? →